Tillkännagivande • Jul 01
DBV Technologies Provides BLA Submission Update For The VIASKIN Peanut Patch In Children Aged 4 Through 7 Years DBV Technologies provided an update on the Biologics License Application (BLA) submission seeking marketing approval of the VIASKIN Peanut Patch in children aged four through seven years. Over recent weeks, DBV has had ongoing detailed and iterative engagement with the U.S. Food and Drug Administration (FDA) with the objective of ensuring a complete, efficient, and timely review of the Company’s upcoming BLA for children aged four through seven years. DBV and the FDA have collaborated through meetings, information exchanges, and filings for the VIASKIN Peanut Patch Investigational New Drug Application (IND). Through this process and based on its review, DBV received valuable, actionable input from the FDA, specific to the organization, mapping, and formatting of existing data sets for the CMC and biostatistical elements of the BLA. The FDA has not requested additional data. The Company will take the required time to incorporate that feedback and now anticipates filing of the BLA to occur in the third quarter of 2026. The VIASKIN Peanut Patch is a novel and complex product with no regulatory precedent. Epicutaneous immunotherapy (EPIT), the VIASKIN Peanut Patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. The Company’s food allergy programs include ongoing clinical trials of VIASKIN Peanut Patch in toddlers (1 through 3 years of age) and children (4 through 7 years of age) with peanut allergy. Tillkännagivande • Jun 09
DBV Technologies Presents New Positive Data from VITESSE Study and Previews Recently Initiated THRIVE Study at EAACI Congress 2026 DBV Technologies announced new positive data from its Phase 3 VITESSE study of the VIASKIN Peanut Patch in children ages 4 through 7 years with peanut allergy, and a preview of the design of its Phase 2 THRIVE study in infants ages 6 through 12 months with peanut allergy. Both will be presented in oral abstract sessions at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026, taking place June 12 – 15, 2026 in Istanbul, Turkey. In the Phase 3 VITESSE study, VIASKIN Peanut Patch demonstrated statistically significant efficacy vs. placebo in the subgroups of children with peanut allergy who also had another common atopic condition, including asthma, concomitant food allergy, or atopic dermatitis. DBV will also present the clinical trial design of its recently initiated THRIVE study, which will assess the efficacy and safety of the VIASKIN Peanut Patch in achieving ad lib consumption of peanuts in infants ages 6 through 12 months with peanut allergy following three years of treatment. This scientific presentation details a subgroup analysis of participants in the successful VITESSE Phase 3 study of the VIASKIN Peanut Patch in children ages 4 through 7 years with peanut allergy and another atopic comorbidity, including asthma, additional food allergies or atopic dermatitis. In the VITESSE study, 654 participants were randomized to receive the VIASKIN Peanut Patch (n=438) or placebo (n=216). Atopic comorbidities were highly prevalent; specifically, 35.8% (n=234) of participants had asthma, 56.6% (n=370) had additional food allergies, and 61.8% (n=404) had atopic dermatitis. At 12 months, significantly more participants treated with the VIASKIN Peanut Patch met the response criteria compared with those who received placebo across all concomitant atopic comorbidity subgroups. Tillkännagivande • Jun 03
DBV Technologies Screens First Participant In Thrive Phase 2 Study Of The Viaskin Peanut Patch In Infants With Peanut Allergy DBV Technologies announced that the first participant has been screened in the THRIVE Phase 2 clinical study evaluating the efficacy and safety of the VIASKIN Peanut Patch in achieving ad lib consumption of dietary peanut in infants ages 6 through 12 months in achieving ad lib consumption of dietary peanut. The study is evaluating the efficacy and safety of the VIASKIN Peanut Patch in achieving ad lib consumption of dietary peanut in infants ages 6 through 12 months with peanut allergy. THRIVE is a Phase 2, single-arm, open-label study to assess the efficacy and safety of the VIASKIN Peanut Patch in achieving ad lib consumption of dietary peanut in infants ages 6 through 12 months with peanut allergy. All participants will have the VIASKIN Peanut Patch applied daily for 36 months while maintaining a peanut-free diet. At 36-months, a peanut food challenge will be conducted to determine the peanut consumption regimen for the next 12-months (months 37-48 of the study). Depending on the results of the peanut food challenge, some participants will enter the 12-month peanut consumption period without further VIASKIN Peanut Patch treatment, while others will continue to wear the patch. “Ad lib” peanut consumption is defined in the protocol using prespecified criteria based on tolerated single-sitting intake, longitudinal consumption patterns, and caregiver-reported outcomes. Based on individual participant tolerability to peanut consumption, some participants may be considered to reach “ad lib” peanut consumption (i.e., consuming peanut as much and as often as desired) during the fourth year of the study. Board Change • May 20
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Director Tim Morris was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • May 05
First quarter 2026 earnings released: US$0.11 loss per share (vs US$0.26 loss in 1Q 2025) First quarter 2026 results: US$0.11 loss per share. Net loss: US$47.6m (loss widened 76% from 1Q 2025). Revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe. Breakeven Date Change • May 04 The 6 analysts covering DBV Technologies previously expected the company to break even in 2028. New consensus forecast suggests losses will reduce by 2.8% per year to 2027. The company is expected to make a profit of US$77.5m in 2028. Average annual earnings growth of 72% is required to achieve expected profit on schedule.
Tillkännagivande • May 01
DBV Technologies S.A., Annual General Meeting, Jun 03, 2026 DBV Technologies S.A., Annual General Meeting, Jun 03, 2026. Location: 107 avenue de la republique, chatillon France Board Change • Apr 14
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Tim Morris was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Mar 29
Full year 2025 earnings released: US$1.05 loss per share (vs US$1.17 loss in FY 2024) Full year 2025 results: US$1.05 loss per share. Net loss: US$146.9m (loss widened 29% from FY 2024). Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe. Board Change • Mar 23
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Tim Morris was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Board Change • Mar 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Tim Morris was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Tillkännagivande • Mar 02
Dbv Technologies Highlights Additional Data from Successful Phase 3 Vitesse Study At the Aaaai 2026 Annual Meeting DBV Technologies announced that the company shared additional positive data from the successful Phase 3 VITESSE clinical trial as an oral presentation at the American Academy of Allergy, Asthma, and Immunology (AAAAI) 2026 Annual Meeting, in Philadelphia, PA. VITESSE, the food allergy immunotherapy trial to date, is a Phase 3 study assessing DBV's VIASKIN®? Peanut Patch for the treatment of peanut-allergic children aged 4 to 7 years. The VITESSE study met its primary endpoint whereby VIASKIN®?Peanut demonstrated a statistically significant treatment effect (pp. The increases in eliciting dose seen are clinically meaningful and may reflect a reduced risk of an allergic reaction. Conversely, nearly four times as many children on placebo saw their eliciting dose decrease, becoming more sensitized over the twelve-month period. These results not only support the VIASKIN®? peanut Patch as a potential treatment option for peanut-allergic children, if approved, but also reinforce the importance of prioritizing a proactive treatment for this specific patient population. Board Change • Dec 09
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Tim Morris was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Board Change • Nov 19
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Tim Morris was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Tillkännagivande • Nov 04
DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial, Effective November 3, 2025 DBV Technologies announced the appointment of Kevin Trapp as Chief Commercial Officer, effective immediately. In his role, Mr. Trapp will report directly to Daniel Tasse, Chief Executive Officer, as a member of the executive team and will lead all aspects of global commercial strategy and execution for the Viaskin(R) Peanut patch. DBV expects to submit a Biologics License Application (BLA) submission for children 4-7 years-old living with peanut allergy in the first half of 2026, followed by an anticipated BLA submission for 1-3 year-olds in the second half of the year. Kevin Trapp is an accomplished commercial executive with more than 30 years of experience in the biopharmaceutical industry. Before rejoining DBV, Kevin served as a consultant to the Company in his most recent role as Managing Director at Biotech Value Advisors (BVA) where he advised biotechnology boards of directors and executive leadership with product strategy, launch planning, and business evaluation. He built his career at Bristol-Myers Squibb (BMS), where he held roles of increasing responsibility across finance, sales, marketing, and general management. During his time at BMS, he managed a ~$4 billion U.S. specialty and primary care portfolio and was a key stakeholder in the planning and subsequent launches of more than 10 products and indications - including Abilify(R), Atripla(R), Reyataz(R), Orencia(R), and Daklinza(R). Mr. Trapp earned a bachelor's degree from the University of Connecticut School of Business and completed the General Management Program from the European Centre for Executive Development (CEDEP) at INSEAD. New Risk • Oct 31
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$98m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$98m free cash flow). Shares are highly illiquid. Shareholders have been substantially diluted in the past year (76% increase in shares outstanding). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$81m net loss in 3 years). Reported Earnings • Oct 31
Third quarter 2025 earnings released: US$0.24 loss per share (vs US$0.32 loss in 3Q 2024) Third quarter 2025 results: US$0.24 loss per share. Net loss: US$33.2m (loss widened 8.9% from 3Q 2024). Revenue is forecast to grow 63% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Biotechs industry in Europe. Board Change • Oct 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Tim Morris was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Board Change • Oct 06
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Tim Morris was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Tillkännagivande • Sep 19
DBV Technologies Announces Resignation of Daniel Soland as a Member of its Board of Directors, Effective September 18, 2025 DBV Technologies announced the resignation of Daniel Soland, as a member of its Board of Directors, effective September 18, 2025. 
